TEVA Stock Recent News

Teva's betting big on biosimilars and specialty drugs, with AUSTEDO and UZEDY leading the charge. Management's $700 million cost-cutting plan is on track, aiming for a 30% operating margin by 2027. Recent FDA wins, like SELARSDI, show Teva's pushing into high-margin markets.

TEVA shares rise despite mixed first-quarter results. Teva lowers the higher end of its 2025 sales guidance while increasing the lower end of its EPS range.

Shares of Teva Pharmaceutical (TEVA 8.44%) are surging on Wednesday. The company's stock is up 9.2% as of 1:15 p.m.

The drugmaker reported first-quarter earnings that beat expectations and raised its full-year guidance.

Teva Pharmaceutical Industries Ltd TEVA stock is trading higher on Wednesday after the company's first-quarter 2025 financial results. Here are the details.

Richard Francis, Teva Pharma CEO, joins 'Money Movers' to discuss the company's quarterly earnings results, any pharma shortages in the U.S., and much more.

Shares in Teva Pharmaceutical Industries (NASDAQ:TEVA) rose 5% after publishing first-quarter earnings, where the Israeli company said US tariffs are expected to have an "immaterial impact".  The Tel Aviv-based drugs maker reported revenue of $3.9 billion for the quarter, a 5% increase in local currency terms as key growth products continued to perform well, with operating income swinging to $519 million from a loss of $218 million a year ago.

Teva Pharmaceutical Industries Limited (NYSE:TEVA ) Q1 2025 Earnings Call May 7, 2025 8:00 AM ET Company Participants Christopher Stevo - SVP, IR Richard Francis - President & CEO Eric A. Hughes - EVP, Global R&D and Chief Medical Officer Eli Kalif - EVP & CFO Conference Call Participants David Amsellem - Piper Sandler Jason Gerberry - Bank of America Umer Raffat - Evercore ISI Ashwani Verma - UBS Investment Bank Christopher Schott - J.P.

While the top- and bottom-line numbers for Teva Pharmaceutical Industries (TEVA) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Teva Pharmaceutical Industries reported a slightly larger than expected rise in first-quarter profit, helped by strong sales gains in a trio of its branded drugs to treat migraines, Huntington's disease and schizophrenia.